JohnELevineMDM.S.

Pediatric Hematology & Oncology • New York, NY

Director of BMT Clinical Research

Join to view full profile

Dr. Levine is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Levine's full profile

Already have an account?

Office
1425 Madison Avenue, 3rd Floor
Room L3-17/Box 1410
New York, NY 10029
Phone+1 212-241-3429
Is this information wrong?

Education & Training

Memorial Sloan Kettering Cancer Center1992 - 1995
Children's Hospital Los AngelesResidency, Pediatrics, 1989 - 1992
Eastern Virginia Medical SchoolClass of 1989

Certifications & Licensure

FL State Medical License 2020 - Present
CA State Medical License 1990 - Present
NY State Medical License 1992 - 2024
PA State Medical License 2016 - 2018
MI State Medical License 1995 - 2017
American Board of Pediatrics Pediatric Hematology-Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012

Clinical Trials

Recombinant Human Keratinocyte Growth Factor in Unrelated and Related Transplants Start of enrollment: 2002 Sep 01
Completed
Phase 1, Phase 2
The Use of Etanercept (Enbrel®) in the Treatment of Acute Graft-Versus-Host Disease Start of enrollment: 2003 Oct 01
Completed
Phase 2
Study of Etanercept for the Prevention of Complications Resulting From Hematopoietic Stem Cell Transplantation (HSCT) Start of enrollment: 2004 Aug 01
Completed
Phase 2
Study of High-Dose Chemotherapy With Bone Marrow or Stem Cell Transplant for Rare Poor-Prognosis Cancers Start of enrollment: 1997 Jan 01
Completed
Phase 2
Study of Low-Intensity Conditioning for Allogeneic Stem Cell Transplant Start of enrollment: 2003 Apr 01
Completed
Phase 2
Study of Low Intensity Conditioning and Immunotherapy for High-Risk Cancers of the Blood Start of enrollment: 2000 Mar 01
Terminated
Phase 2
Low-Intensity Preparation and Allogeneic Transplant in Patients With Cancers of the Blood Start of enrollment: 2000 Mar 01
Completed
Phase 2
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302) Start of enrollment: 2005 Sep 01
Completed
Phase 2
Addition of Etanercept and Extracorporeal Photopheresis (ECP) to Standard Graft-Versus-Host Disease (GVHD) Prophylaxis in Stem Cell Transplant Start of enrollment: 2009 Mar 01
Completed
Phase 2
Evaluating the Safety and Effectiveness of Bone Marrow Transplants in Children With Sickle Cell Disease (BMT CTN 0601) Start of enrollment: 2008 Aug 01
Completed
Phase 2
Caspofungin Acetate, Fluconazole, or Voriconazole in Preventing Fungal Infections in Patients Following Donor Stem Cell Transplant Start of enrollment: 2013 Mar 21
Completed
Phase 3
Multicenter Study Of Natalizumab Plus Standard Steroid Treatment For High Risk Acute Graft-Versus-Host Disease Start of enrollment: 2016 Aug 01
Completed
Phase 2
Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients Start of enrollment: 2014 Aug 14
Completed
Phase 2
Bone Marrow Transplantation vs Standard of Care in Patients With Severe Sickle Cell Disease (BMT CTN 1503) Start of enrollment: 2016 Nov 01
Completed
Phase 2
A Proof of Concept Pilot Trial of Alpha-1-Antitrypsin for Pre-Emption Of Steroid-Refractory Acute GVHD Start of enrollment: 2018 Aug 17
Completed
Phase 2
Itacitinib for Low Risk GVHD Start of enrollment: 2019 Mar 25
Completed
Phase 2
T-Guard as Treatment for Steroid Refractory Acute GVHD (BMT CTN 1802) Start of enrollment: 2019 Nov 21
Terminated
Phase 3
Pediatric GVHD Low Risk Steroid Taper Trial Start of enrollment: 2022 Oct 20
Recruiting
Phase 2
Roles: Sponsor-Investigator, Principal Investigator
A Study to Compare T-Guard vs Ruxolitinib for Treatment of Steroid-Refractory Acute Graft-vs-Host Disease (BMT CTN 2002) Start of enrollment: 2022 Jun 16
Terminated
Phase 3
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

A Day 14 Endpoint for Acute GVHD Clinical Trials.
Al Malki, M. M., Nikolaos Spyrou, Yu Akahoshi, Steven Kowalyk, George Morales, Rahnuma Beheshti, Paibel Aguayo-Hiraldo, Monzr M Al Malki, Francis Ayuk, Peter Bader, Ja...> ;Transplantation and Cellular Therapy. 2024 Apr 1
A Validated Risk Stratification That Incorporates MAGIC Biomarkers Predicts Long-Term Outcomes in Pediatric Patients with Acute GVHD.
Kapoor, U., Muna Qayed, Urvi Kapoor, Scott Gillespie, Adrianna Westbrook, Paibel Aguayo-Hiraldo, Francis A Ayuk, Mina Aziz, Janna Baez, Hannah Choe, Zachariah DeFilipp...> ;Transplantation and Cellular Therapy. 2024 Mar 27
Defining and Grading Infections in Clinical Trials Involving Hematopoietic Cell Transplantation: A Report From the BMT CTN Infectious Disease Technical Committee.
Zainab Shahid, Aaron M Etra, John E Levine, Marcie L Riches, Aliyah Baluch, Joshua A Hill, Ryo Nakamura, Amir A Toor, Celalettin Ustun, Jo-Anne H Young, Miguel-Angel P...> ;Transplantation and Cellular Therapy. 2024 Mar 6
Inhibition of RIP1 improves immune reconstitution and reduces GVHD mortality while preserving graft-versus-leukemia effects.
Prado-Acosta, M., Jeong, S., Utrero-Rico, A., Goncharov, T., Webster, J., Holler, E., Morales, G., Rothenberg, M., Vucic, D., Dellepiane, S., Levine, J., Ferrara, J.> ;Science Translational Medicine. 2023 Dec 20
Galectin-3 predicts acute GvHD and overall mortality post reduced intensity allo-HCT: a BMT-CTN biorepository study.
Philip L McCarthy, Kristopher M Attwood, Xiaojun Liu, George L Chen, Hans Minderman, Amin Alousi, Asad Bashey, Robert Lowsky, David B Miklos, John Hansen, Peter Wester...> ;Bone Marrow Transplantation. 2024 Mar 1
Planning GvHD preemptive therapy: risk factors, biomarkers, and prognostic scores.
Rozmus, J., Schultz, K., Levine, J.> ;Hematology. American Society of Hematology. Education Program. 2023 Dec 8
1 citations
Anti-CD3/CD7 immunoconjugate (T-Guard) for severe, steroid-refractory GVHD: final report of BMT CTN 2002.
Gabrielle Meyers, Mehdi Hamadani, Michael Martens, Haris Ali, Patrice Chevallier, Hannah Choe, Andrew C Harris, Ernst Holler, Eric van Hooren, Willem Klaassen, Eric Le...> ;Bone Marrow Transplantation. 2023 Dec 1
2 citations
Phase 2 study of natalizumab plus standard corticosteroid treatment for high-risk acute graft-versus-host disease.
Al Malki, M. M., Monzr M Al Malki, Kaitlyn London, Janna Baez, Yu Akahoshi, William J Hogan, Aaron Etra, Hannah Choe, Elizabeth Hexner, Amelia Langston, Sunil Abhyanka...> ;Blood Advances. 2023 Sep 12
2 citations
The utility of biomarkers in acute GVHD prognostication.
Nikolaos Spyrou, Yu Akahoshi, Francis Ayuk, Ernst Holler, Hannah Choe, Aaron Etra, William J Hogan, Wolf Rösler, Elizabeth Hexner, Zachariah DeFilipp, Ran Reshef, Chan...> ;Blood Advances. 2023 Sep 12
2 citations
Incidence, clinical presentation, risk factors, outcomes, and biomarkers in de novo late acute GVHD.
Yu Akahoshi, Nikolaos Spyrou, William J Hogan, Francis Ayuk, Zachariah DeFilipp, Daniela Weber, Hannah K Choe, Elizabeth O Hexner, Wolf Rösler, Aaron M Etra, Karamjeet...> ;Blood Advances. 2023 Aug 22
1 citations
More evidence for low-dose IL-2 for chronic GVHD in children.
John E Levine> ;Blood Advances. 2023 Aug 22
1 citations
Children's Oncology Group's 2023 blueprint for research: Cellular therapy and stem cell transplantation.
Carrie L Kitko, Catherine M Bollard, Mitchell S Cairo, Joseph Chewning, Terry J Fry, Michael A Pulsipher, Shalini Shenoy, Donna A Wall, John E Levine> ;Pediatric Blood & Cancer. 2023 Sep 1
3 citations
Reg3α concentrations at day of allogeneic stem cell transplantation predict outcome and correlate with early antibiotic use.
Daniela Weber, Markus Weber, Elisabeth Meedt, Sakhila Ghimire, Daniel Wolff, Matthias Edinger, Hendrik Poeck, Andreas Hiergeist, André Gessner, Francis Ayuk, Wolf Roes...> ;Blood Advances. 2023 Apr 11
1 citations
Prognostic Biomarkers for Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome in Myeloablative Allogeneic Hematopoietic Cell Transplantation: Results from t...
Santosh Putta, Bradford A Young, John E Levine, Ran Reshef, Ryotaro Nakamura, Christopher Strouse, Miguel-Angel Perales, Alan Howard, Polly Pine, Ju Shi, Peixin Zhang,...> ;Transplantation and Cellular Therapy. 2023 Mar 1
2 citations
Acute GVHD: New approaches to clinical trial monitoring.
Nikolaos Spyrou, John E Levine, James L M Ferrara> ;Best Practice & Research. Clinical Haematology. 2022 Dec 1
4 citations
Monitoring Neurocognitive Functioning After Pediatric Cellular Therapy or Hematopoietic Cell Transplant: Guidelines From the COG Neurocognition in Cellular Therapies T...
Hannah-Lise T Schofield, Vanessa A Fabrizio, Suzanne Braniecki, Wendy Pelletier, Hesham Eissa, Beverly Murphy, Joseph Chewning, Karen D Barton, Leanne M Embry, John E ...> ;Transplantation and Cellular Therapy. 2022 Oct 1
Inefficiency of two-stage designs in phase II oncology clinical trials with high proportion of inevaluable patients.
Lingyun Ji, Jennifer Whangbo, John E Levine, Todd A Alonzo> ;Contemporary Clinical Trials. 2022 Sep 1
31 citations
Sorafenib in Combination With Standard Chemotherapy for Children With High Allelic Ratio/ITD+ Acute Myeloid Leukemia: A Report From the Children's Oncology Group Proto...
Jessica A Pollard, Todd A Alonzo, Robert Gerbing, Patrick Brown, Elizabeth Fox, John Choi, Brian Fisher, Betsy Hirsch, Samir Kahwash, Kelly Getz, John Levine, Lisa Eid...> ;Journal of Clinical Oncology. 2022 Jun 20
8 citations
Assessment of systemic and gastrointestinal tissue damage biomarkers for GVHD risk stratification.
Aaron Etra, Stephanie Gergoudis, George Morales, Nikolaos Spyrou, Jay Shah, Steven Kowalyk, Francis Ayuk, Janna Baez, Chantiya Chanswangphuwana, Yi-Bin Chen, Hannah Ch...> ;Blood Advances. 2022 Jun 28
3 citations
Mesenchymal stromal cell therapy for acute respiratory distress syndrome due to coronavirus disease 2019.
Stacey-Ann Whittaker Brown, Camelia Iancu-Rubin, Adam Aboelela, Alex Abrahams, Elizabeth Burke, Tiffany Drummond, Fred Grossman, Silviu Itescu, Jonathan Lagdameo, Jung...> ;Cytotherapy. 2022 Aug 1
3 citations
Decoupling blood telomere length from age in recipients of allogeneic hematopoietic cell transplant in the BMT-CTN 1202.
Tsung-Po Lai, Simon Verhulst, Casey L Dagnall, Amy Hutchinson, Stephen R Spellman, Alan Howard, Hormuzd A Katki, John E Levine, Wael Saber, Abraham Aviv, Shahinaz M Ga...> ;Frontiers in Immunology. 2022 Jan 1
1 citations
Lessons learned from early closure of a clinical trial for steroid-refractory acute GVHD.
Gabrielle Meyers, Mehdi Hamadani, Michael Martens, Haris Ali, Hannah Choe, Peter Dawson, Andrew C. Harris, Eric van Hooren, Willem Klaassen, Eric S. Leifer, Margaret L...> ;Bone Marrow Transplantation. 2021 Nov 23
8 citations
Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2021: Looking Forward as the Network Celebrates its 20th Year
Helen E. Heslop, Edward A. Stadtmauer, John E. Levine, Karen K. Ballen, Yi-Bin Chen, Amy E. DeZern, Mary Eapen, Mehdi Hamadani, Betty K. Hamilton, Parameswaran Hari, R...> ;Transplantation and Cellular Therapy. 2021 Nov 1
3 citations
Mesenchymal stromal cell therapy induces high responses and survival in children with steroid refractory GVHD and poor risk biomarkers.
Stelios Kasikis, Janna Baez, Isha Gandhi, Stephan A. Grupp, Carrie L. Kitko, Steven Kowalyk, Pietro Merli, George Morales, Michael A. Pulsipher, Muna Qayed, Matthias W...> ;Bone Marrow Transplantation. 2021 Sep 1
11 citations
Evaluation of Elafin as a Prognostic Biomarker in Acute Graft-versus-Host Disease
Makda Getachew Zewde, George Morales, Isha Gandhi, Umut Ozbek, Paibel Aguayo-Hiraldo, Francis Ayuk, Janna Baez, Chantiya Chanswangphuwana, Hannah Choe, Zachariah DeFil...> ;Transplantation and Cellular Therapy. 2021 Aug 30
Join now to see all

Journal Articles

Genetic Mechanisms of Target Antigen Loss in CAR19 Therapy of Acute Lymphoblastic Leukemia
John E Levine, Muna Qayed, Stephan A Grupp, Eneida R Nemecek, Stella M Davies, Michael R Verneris, Michael Boyer, Jeffrey A Engelman, Nature

Abstracts/Posters

Obesity-Induced Microbiome Alterations Result in Severe Gastrointestinal Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation
John E. Levine, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
The MAGIC Algorithm Probability (MAP): A Novel Laboratory Biomarker for the Response to Treatment of Acute Graft-Versus-Host Disease
John E. Levine, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Sorafenib in Combination with Standard Chemotherapy for Children with High Allelic Ratio FLT3/ITD+ AML Improves Event-Free Survival and Reduces Relapse Risk: A Report ...
John E. Levine, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Press Mentions

Everything You Need to Know About Graft-Versus-Host DiseaseJanuary 13th, 2023
Mount Sinai Researchers Find New, Safer Treatment for Serious Side Effect of Bone Marrow TransplantDecember 13th, 2022
An Experimental Cancer Treatment Leaves Two Patients 'Cured' After 10 YearsFebruary 18th, 2022
Join now to see all

Grant Support

Phase II Study Of A Novel GVHD Prevention Strategy: Etanercept And PhotopheresisNational Heart, Lung, And Blood Institute2011–2012
Cellular Immunotherapy For Hematologic MalignancyNational Cancer Institute2001–2006
Treatment Of Graft-Versus-Host Disease Using EnbrelFood And Drug Administration2005